Integer (ITGR) Q3 2024 earnings summary

Executive summary

• Q3 2024 sales grew 9% year-over-year to $431 million, with adjusted operating income up 17% and adjusted EPS up 11%; year-to-date sales reached $1.267 billion, up 10%, and adjusted operating income rose 23%.

• Income from continuing operations for Q3 was $36.3 million ($1.01/diluted share), up 29% year-over-year, and $88.1 million ($2.49/diluted share) for nine months, up 35%.

• Completed or agreed to divest Electrochem for $50 million, transitioning to a pure-play medical technology company; results now presented as discontinued operations.

• Promoted Payman Khales to COO and Andrew Senn to President of Cardio and Vascular, effective Q1 2025.

• Achieved above-market sales growth, margin expansion, and leverage ratio at 3.0x, within target range.

Financial highlights

• Q3 2024 sales: $431–$431.4 million, up 8.7–9% year-over-year; organic growth 4%.

• Q3 2024 adjusted EBITDA: $96 million, up 18%; adjusted operating income: $76 million, up 17%.

• Q3 2024 adjusted net income: $50 million; adjusted EPS: $1.43, up 11%.

• Year-to-date sales: $1.267 billion, up 10% reported and 6% organic.

• Year-to-date adjusted EBITDA: $266 million, up 22%; adjusted operating income: $209 million, up 23%.

• Year-to-date adjusted net income: $133 million; adjusted EPS: $3.87, up 21%.

• Gross margin for Q3 and YTD: 27.0%, up from prior year.

• Operating income for Q3: $58 million (+18.9% YoY); nine months: $151.2 million (+26.2% YoY).

Outlook and guidance

• 2024 sales expected at $1.707–$1.727 billion, up 10–11% year-over-year; organic growth 7–8%.

• Adjusted operating income guidance raised to $280–$288 million, up 18–22%.

• Adjusted EBITDA expected at $358–$368 million, up 18–21%.

• Adjusted net income expected at $181–$188 million; adjusted EPS $5.24–$5.43, up 14–18%.

• Cash flow from operations expected at $195–$205 million; free cash flow $90–$100 million, up 49–65%.

• Year-end net total debt expected at $970–$980 million; leverage ratio 2.6–2.7x trailing four-quarter adjusted EBITDA.

• Adjusted effective tax rate expected at 18.0–19.0%.